Type i interferon signaling in malignant blasts contributes to treatment efficacy in aml patients

HIGHLIGHTS

• who: Peter Holicek from the (UNIVERSITY) have published the research: Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients, in the Journal: (JOURNAL) of 17/Nov/2022
• what: The authors report that peripheral blood mononuclear cells (PBMCs) from patients with AML express higher type I IFN levels that their counterparts from healthy donors, with malignant blasts being the major type I IFN source.
• how: To this aim the authors compared the phosphorylation status of the TLR3 signal transducer TANK binding kinase 1 (TBK1) in 3 patients with AML . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.